StockNews.AI
TMCI
StockNews.AI
194 days

Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

1. Treace will release Q4 2024 results on Feb 27, 2025. 2. The company’s procedures target 67 million Americans with bunions. 3. 1.1 million Americans are annual surgical candidates for Treace's treatments. 4. Treace is expanding its product line, including SpeedPlate™ implants. 5. A conference call will address financial results and investor inquiries.

5m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results may indicate growth. Historically, positive earnings reports boost stock prices.

How important is it?

Earnings announcements significantly impact stock valuations. Higher demand for Treace’s solutions suggests potential revenue growth.

Why Short Term?

The upcoming earnings date likely influences short-term investor sentiment. Recent earnings surprises in healthcare often lead to immediate price movements.

Related Companies

TMCISNNZBH
February 06, 2025 16:15 ET  | Source: Treace Medical Concepts, Inc. PONTE VEDRA, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Thursday, February 27, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/. Internet Posting of Information Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace. About Treace Medical Concepts Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com. To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram. Contacts:Treace Medical ConceptsMark L. HairChief Financial Officermhair@treace.net(904) 373-5940 Investors:Gilmartin GroupVivian Cervantes IR@treace.net

Related News